Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that ALRN-6924 effectively protected human hair follicles from cyclophosphamide-induced damage in an ex vivo setting, suggesting it may reduce both acute and permanent chemotherapy-induced alopecia.

This study found that a lotion containing an alpha lipoic acid derivative increased hair diameter in chemotherapy patients with gastric or colorectal cancer, while those not using the lotion had more pronounced hair loss, suggesting potential benefits in managing chemotherapy-induced alopecia.

The study suggests that refractory chronic alopecia areata cases have more infiltrating skin resident memory T cells, and using a JAK inhibitor may be an effective treatment option.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This study investigated the efficacy and safety of a gel combining topical calcipotriol and steroid for alopecia areata. It found the combination worked similarly to steroids alone in reducing hair loss, but with fewer side effects.

In this study, researchers used Mendelian randomization to find a significant genetic association between rheumatoid arthritis and an increased risk of alopecia areata, suggesting RA patients should be vigilant for potential AA development.

This study suggests that scalp rolling could be a promising and affordable adjuvant treatment for alopecia areata, potentially promoting hair regrowth by enhancing the effects of topical medications and inducing collagen.

This study found that the alcoholic extract of Eclipta alba exhibited dose-dependent antianaphylactic effects in animal models, possibly due to membrane stabilization and reduced histamine release.

This study describes a new treatment algorithm for alopecia areata that includes both disease severity and quality-of-life considerations, highlighting recent therapeutic advances and the need for future validation and access equity.

In this study, researchers presented a novel therapeutic approach for androgenetic alopecia combining AR-PROTAC degradation with regenerative strategies and evaluated the potential of GT20029 as a topical treatment, proposing a three-phase protocol and future research hypotheses.

This study suggests that male sex and androgenic steroid use increase the risk of atrial arrhythmias in individuals with arrhythmogenic right ventricular cardiomyopathy, especially those with desmosomal gene mutations.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.

EDA2R gene linked to hair loss.

In this study, nitrogen starvation in Chlorella sp. FC2 IITG led to increased lipid accumulation by altering the expression of enzymes involved in various metabolic pathways, suggesting potential for genetic engineering of microalgae.

A new microneedle patch effectively and safely treats alopecia areata.

A specific RNA molecule blocks hair growth by affecting a protein related to hair loss conditions.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

This study found that targeting the AR/miR-128-3p/IGF-1 pathway with ASLNC168501 shows potential for treating androgenetic alopecia by restoring hair follicle stem cell function and promoting hair regeneration.

This source reports that the approval of baricitinib and ritlecitinib, which are JAK inhibitors, has marked a significant advancement in treating severe alopecia areata (AA), and suggests that additional treatments with new mechanisms may further improve patient outcomes in the future.

This study found that different stabilizing mutations in Aux/IAA proteins affect root hair development in Arabidopsis by disrupting the auxin response and suggest a model where the relative abundance of these proteins determines root hair initiation.

This study observed greater clinical improvement in patients with alopecia areata who received individualized homoeopathic constitutional treatment compared to those who received Acid Phos, but further research with objective measures is needed to confirm these findings.

This study developed the Alopecia Areata Children's Quality of Life Index (AAcQLI) to assess quality of life in children with alopecia areata, demonstrating good reliability and validity in initial tests.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

This case study reports that a man with severe patch-type alopecia areata initially responded to baricitinib treatment but experienced a relapse despite ongoing therapy.

In this study, no association was found between the AR gene and type II androgenetic alopecia in Egyptian women, suggesting it is not a useful biomarker for predisposition.

This study found that alopecia areata patients with a CCHCR1 gene variant had higher recurrence rates and structural abnormalities in hair compared to those without the variant.

This study developed dissolving microneedles incorporating a new AR degrader for treating androgenetic alopecia, showing that a single application leads to superior hair regeneration compared to daily minoxidil, without systemic toxicity or androgen-related issues.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

This study reports that two phase III trials demonstrated the effectiveness of the oral Janus kinase inhibitor baricitinib at 2 mg or 4 mg daily for treating severe alopecia areata in adults, marking a potential advance in managing this condition.